title: Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.
abstract: New antitumour immunotherapy strategies for stage iv metastatic melanoma include ipilimumab, a monoclonal antibody against ctla-4. Patterns of response with cancer immunotherapy differ from those with cytotoxic chemotherapy. We present two cases of long-duration immune-related responses with ipilimumab in a phase ii trial. A 66-year-old woman with multiple lung metastases from a scalp primary melanoma received 4 doses of ipilimumab with mixed clinical response. However, after the first maintenance dose, she developed severe ileitis and colitis that responded to steroid therapy. Four months later, she had surgery and radiotherapy for a single brain metastasis. Radiologically, stable disease continued for 36 months after the last ipilimumab dose, and partial response for 5 years after ipilimumab start. A 54-year-old man with cervical lymph node and pulmonary metastases from a scalp primary melanoma received three induction doses of ipilimumab. He developed alopecia universalis and widespread vitiligo, and he discontinued treatment because of hypophysitis. Maintenance ipilimumab was started after a 6-month drug-free interval, with no further adverse events over 15 cycles. At week 12, computed tomography imaging showed no lung metastases and partial response in a supraclavicular lymph node, which was positive on positron-emission tomography. Five years after starting ipilimumab, the supraclavicular lymph node was calcified, and the patient was off steroid therapy and asymptomatic. The foregoing patients demonstrate long responses with ipilimumab (in association with delayed severe colitis in one case, and a constellation of immune events, including alopecia universalis in another). Re-treatment with ipilimumab may be possible even after significant immune adverse events.
authors.forename: H
authors.initials: H
authors.lastname: Assi
authors.forename: K S
authors.initials: KS
authors.lastname: Wilson
keywords: Ipilimumab; immune response; melanoma; safety
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Ann Oncol. 2010 Aug;21(8):1712-1717
references.pmid: 20147741
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5591-8
references.pmid: 19671877
references.citation: Cancer. 2007 Dec 15;110(12):2614-27
references.pmid: 18000991
references.citation: Cancer Immun. 2008 Jan 17;8:1
references.pmid: 18198818
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Lancet Oncol. 2010 Feb;11(2):155-64
references.pmid: 20004617
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2691-7
references.pmid: 22614989
references.citation: Clin J Oncol Nurs. 2011 Aug;15(4):393-403
references.pmid: 21810572
references.citation: Melanoma Res. 2007 Apr;17(2):117-27
references.pmid: 17496787
references.citation: Melanoma Res. 2011 Apr;21(2):152-9
references.pmid: 21317818
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: Melanoma Res. 2012 Jun;22(3):263-70
references.pmid: 22516968
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Adv Immunol. 2006;90:297-339
references.pmid: 16730267
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references.pmid: 19917835
references.citation: Arch Dermatol. 2006 Feb;142(2):166-72
references.pmid: 16490844